Vasundhara Rasayans FY26 net profit rises 36% to ₹578.91 lakh
Vasundhara Rasayans reported a 36.3% rise in FY26 net profit to ₹578.91 lakh, with revenue increasing to ₹3,572.31 lakh. Q4 net profit surged to ₹247.82 lakh from ₹44.63 lakh. The Board appointed Shri Ravi Jain as an Additional Director and approved a manufacturing agreement with PandJ Cretechem Private Limited.

*this image is generated using AI for illustrative purposes only.
Vasundhara Rasayans reported a 36.3% rise in net profit to ₹578.91 lakh for the financial year ended March 31, 2026, compared to ₹424.63 lakh in the prior year. Revenue from operations for FY26 increased to ₹3,572.31 lakh from ₹3,399.01 lakh in FY25. The company’s statutory auditors, M/s. Mamta Jain & Associates, issued an unmodified opinion on the audited financial results.
For the quarter ended March 31, 2026, the company recorded a net profit of ₹247.82 lakh, a significant increase from ₹44.63 lakh in the corresponding quarter of the previous year. Total income for the quarter stood at ₹1,258.38 lakh, up from ₹858.80 lakh in Q4FY25. Earnings per share (EPS) for the full year improved to ₹18.22 from ₹13.36 in the previous year.
The Board of Directors, at its meeting held on May 28, 2026, approved the audited standalone financial results. Based on the recommendation of the Nomination and Remuneration Committee, the Board appointed Shri Ravi Jain as an Additional Director (Non-Executive Independent Director) effective May 28, 2026, for a term of five years subject to shareholder approval. Mr. Ravi Jain is a Graduate with over 10 years of experience in marketing and business development across consumer goods. He has led strategic marketing, brand-building, and customer-acquisition initiatives, and is not related to any other Director on the Board.
Mr. Pradeep Kumar Jain retired as a Non-Executive Independent Director upon completing his second term of five consecutive years. In a strategic move, the Board approved entering into a Memorandum of Understanding cum Loan-Lease Agreement with PandJ Cretechem Private Limited, the holding company. This agreement establishes a manufacturing arrangement for Active Pharmaceutical Ingredients (APIs) at the holding company's facility in Dahej, Gujarat. The Audit Committee had previously approved and recommended this transaction on May 28, 2026.
The Board also reconstituted the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, appointing Mr. Manish Jain as the chairperson of each committee effective May 29, 2026.
Financial Results for FY26
| Particulars | Year Ended 31.03.2026 (₹ in Lakhs) | Year Ended 31.03.2025 (₹ in Lakhs) |
|---|---|---|
| Net Sales/Income from Operations | 3,572.31 | 3,399.01 |
| Total Income | 3,862.69 | 3,634.09 |
| Total Expenses | 3,076.34 | 3,057.36 |
| Profit before tax | 786.35 | 576.73 |
| Net Profit | 578.91 | 424.63 |
| Earnings Per Share (Basic) | 18.22 | 13.36 |
Historical Stock Returns for Vasundhara Rasayans
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.98% | +31.90% | +22.47% | -19.88% | -23.78% | +68.64% |
How will the new manufacturing arrangement with PandJ Cretechem impact Vasundhara Rasayans' production capacity and cost structure?
What specific strategic value will Mr. Ravi Jain's marketing background bring to the company's future growth plans?
Can the significant surge in Q4 net profit be sustained into the next financial year, or was it driven by one-off factors?






























